Sofinnova Partners, a Paris-based life sciences VC firm, raised €650 million ($750 million) in its 11th flagship fund, managing partner Antoine Papiernik tells Axios Pro.
Why it matters: The investor managed to fundraise amid a notoriously volatile market.
